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Abstract
Data on antifungal prophylaxis in paediatric cancer patients at high risk for invasive fungal disease (IFD) are scant. Intermittent adminis-
tration of liposomal amphotericin B (LAMB) has been shown to be safe and effective in adult patients with haematological malignancies.
We prospectively evaluated the safety and efﬁcacy of prophylactic LAMB at a dosage of 2.5 mg/kg twice weekly in children at high risk
for IFD. Efﬁcacy was compared with that in a historical control group of patients with similar demographic characteristics not receiving
LAMB prophylaxis. A total of 46 high-risk patients (24 boys; mean age, 7.7 years) with 187 episodes of antifungal prophylaxis were anal-
ysed. The median duration of neutropenia (<500/lL) was 10 days. LAMB was discontinued in four patients because of acute allergic
reactions. Median values for creatinine and liver enzymes at end of treatment did not differ signiﬁcantly from those at baseline. Hypokal-
aemia (<3.0 mmol/L) occurred with 13.5% of the prophylactic episodes, but was usually mild and always reversible. No proven/probable
IFD occurred in patients receiving LAMB prophylaxis. In comparison, ﬁve proven and two probable IFDs were observed in 45 historical
controls not receiving LAMB prophylaxis (p 0.01). LAMB prophylaxis had no impact on the use of empirical antifungal therapy. Systemic
antifungal prophylaxis with LAMB 2.5 mg/kg twice weekly is feasible and safe, and seems to be an effective approach for antifungal pro-
phylaxis in high-risk paediatric cancer patients.
Keywords: Antifungal prophylaxis, child, invasive fungal disease, liposomal amphotericin B
Original Submission: 8 November 2010; Revised Submission: 17 January 2010; Accepted: 17 January 2011
Editor: E. Roilides
Article published online: 1 February 2011
Clin Microbiol Infect 2011; 17: 1868–1874
10.1111/j.1469-0691.2011.03483.x
Corresponding author: T. Lehrnbecher, Paediatric Haematology
and Oncology, Children’s Hospital III, Johann Wolfgang Goethe Uni-
versity, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
E-mail: Thomas.Lehrnbecher@kgu.de
Introduction
Despite the availability of new antifungal agents, invasive fun-
gal disease (IFD) is still a major cause of morbidity and mor-
tality in paediatric patients undergoing therapy for cancer. In
particular, children treated for high-risk acute lymphoblastic
leukaemia (ALL), acute myeloid leukaemia (AML) or relapsed
acute leukaemia are at high risk for IFD and may beneﬁt
from systemic prophylactic antifungal measures [1,2].
Whereas posaconazole has been demonstrated to decrease
the incidence of IFD in adults undergoing induction therapy
for AML or adult haematopoietic stem cell transplant recipi-
ents with severe graft-versus-host disease [3,4], the optimal
approach to antifungal prophylaxis in paediatric patients is
not at all clear, for several reasons. First, several antifungal
compounds, including posaconazole, are not approved for
children, and a paediatric dosage has not been established
for some of them. Second, the use of antifungal triazoles is
limited by the potentiation of toxicity when they are co-
administered with vinca alkaloids, which constitute a corner-
stone in the treatment of acute paediatric leukaemia [5,6].
Moreover, the use of echinocandins (e.g. micafungin, which is
approved in children for antifungal prophylaxis) is not feasible
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in an outpatient setting, owing to the short half-life of the
compounds, necessitating daily intravenous administration.
Liposomal amphotericin B (LAMB) does not have relevant
drug–drug interactions, and exhibits lower infusional toxicity
and less long-term nephrotoxic side effects than amphoteri-
cin B deoxycholate [7]. Owing to the long-half life and sub-
stantial tissue penetration of the compound, therapeutic
levels of amphotericin B are found in animal tissues for sev-
eral weeks after treatment [8], and measurable plasma con-
centrations have been demonstrated for up to 7 days after
administration of LAMB at a dosage of 10 mg/kg in paediatric
haematopoietic stem cell transplant recipients [9]. We there-
fore hypothesized that LAMB given twice weekly may be a
feasible, safe and effective strategy for antifungal prophylaxis
in paediatric cancer patients at high risk for IFD.
Patients and Methods
Study design
From April 2007 through August 2010, all consecutive chil-
dren treated for high-risk ALL, AML, relapse of ALL or AML,
high-risk non-Hodgkin lymphoma (such as B-cell ALL) and
severe/very severe aplastic anaemia were included in the
analysis, as they were considered to be at high risk for IFD.
All patients with prior treatment of proven/probable IFD
were excluded from the analysis. Systemic antifungal prophy-
laxis consisted of LAMB (2.5 mg/kg over 1 h) twice weekly.
Topical or inhaled antimycotic compounds were not adminis-
tered; patients were not admitted to HEPA-ﬁltered rooms,
and the use of ﬁltered masks outside the ﬁltered areas was
not routinely recommended. The primary endpoint of the
study was the evaluation of feasibility of the protocol in
terms of safety; secondary endpoints were efﬁcacy and the
assessment of drug concentration in a randomly selected
subgroup of patients. Written informed consent for antifun-
gal therapy as part of the medically indicated measures of
supportive care and for data collection was obtained and
documented within the consent procedures for cancer treat-
ment that have been reviewed and approved by the local
Ethics Committee.
The historical control group consisted of consecutive
patients treated from April 2000 through April 2007 for
underlying malignancies comparable to the those of the study
group. For the study population and historical controls, che-
motherapeutic regimens were either identical (e.g. high-risk
ALL or relapsed leukaemia) or were increased in intensity
over time (e.g. for subgroups of AML patients). Medical and
nursing practices did not differ between the study group and
historical controls (e.g. diagnostic testing and nursing prac-
tices). None of the historical controls received amphoteri-
cin B or an echinocandin as antifungal prophylaxis; however,
depending on the comedication, ﬂuconazole or itraconazole
was administered in a number of the analysed episodes.
Analysis of amphotericin B concentrations
For assessment of LAMB plasma concentrations, blood was
drawn 30 min prior to and after administration of LAMB,
immediately centrifuged for 10 min at 1500 g, and stored at
)70C until being assayed. Concentrations of total amphoter-
icin B were measured with a validated HPLC method [10].
Deﬁnitions
The duration of an episode of antifungal prophylaxis was
deﬁned as the period from day 1 of a cycle of chemotherapy
until the day before day 1 of the next cycle of chemother-
apy. Because of the continuous administration of chemother-
apy during induction therapy for ALL, the duration of an
episode of antifungal prophylaxis in these patients was con-
sidered to be from the onset of neutropenia until haemato-
poietic recovery after induction therapy.
Adverse events were analysed according to the NCI Com-
mon Terminology Criteria for Adverse Events [11]. For
example, allergic reactions of grade I/II consisted of skin reac-
tions, whereas symptomatic bronchospasm requiring paren-
teral medication and anaphylaxis were graded as grade III and
IV adverse events, respectively. Creatinine levels up to 1.5
and >1.5)3 times the upper limit of normal (ULN) were cate-
gorized as grade I and II adverse events, respectively, whereas
levels >3–6 · ULN and >6 · ULN were categorized as gra-
de III and IV, respectively. Potassium levels less than the
lower limit of normal ()3.0 mmol/L) were categorized as gra-
de I hypokalaemia, and levels <3.0–2.5 and <2.5 mmol/L as
grade III and IV, respectively. The primary investigators of the
study (K.B. and T.L.) rated the adverse events as related or
not related to treatment with LAMB, respectively.
IFD was deﬁned as proven, probable and possible accord-
ing to the revised deﬁnitions of the European Organization
for Research and Treatment of Cancer/Mycoses Study
Group [12]. Neutropenic patients with fever refractory to
broad-spectrum antibiotics received empirical antifungal ther-
apy according to standard guidelines [13]. Only patients
receiving at least three doses of LAMB were assessed for
efﬁcacy. Patients were followed for the occurrence of IFD
until 2 months after discontinuation of antifungal prophylaxis.
Statistical analysis
Statistical analysis was performed with BiAS Version 9.02
(Epsilon Publishing). Student’s t-test was used to compare
patients receiving LAMB prophylaxis and historical controls.
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Fisher’s exact test was used for subgroups where appropriate.
All statistical tests were two-sided, and a p-value £0.05 was
considered to be statistically signiﬁcant.
Results
Patient characteristics
A total of 44 patients (24 boys; median age, 7.7 years)
received at least one dose of LAMB for antifungal prophy-
laxis; two patients were included twice in the analysis,
because they received antifungal prophylaxis for both pri-
mary and recurrent malignancy (Table 1). The median dura-
tions of the 184 analysed prophylaxis episodes and of
neutropenia (absolute neutrophil count <500/lL) were 24
and 10 days (range, 5–104 days, and 0–52 days), respectively.
Prolonged neutropenia (>10 days) was observed in 126 of
the analysed episodes (68%) (Table 1).
Safety and tolerability
Antifungal prophylaxis with LAMB was prematurely discon-
tinued in four patients (9%), because of allergic reactions.
Whereas mild skin reactions (grade I/II) during the ﬁrst
administration were noted in three patients, a systemic gra-
de III reaction occurred during the third administration of
LAMB in one patient. All other clinical adverse events, such
as fever, nausea, vomiting, or pain, were considered to be
unrelated to the administration of LAMB.
The median level of creatinine at baseline was 0.33 mg/dL
(range, 0.06–1.4 mg/dL), and was signiﬁcantly lower than the
maximum level during LAMB prophylaxis (median (range),
0.45 mg/dL (0.1–1.49 mg/dL), p <0.001), but comparable to
the ﬁrst level assessed after discontinuation of LAMB pro-
phylaxis (median (range), 0.35 mg/dL (0.06–1.4 mg/dL),
p 0.39) (Fig. 1). In seven episodes with normal baseline creat-
inine, levels were above 1.0 mg/dL at the end of treatment
(grade I/II, n = 6 (3.2%); grade III/IV, n = 1 (0.5%)). In the
only patient with an elevated creatinine level at baseline, the
level remained increased at the end of treatment (1.21 and
1.38 mg/dL, respectively). Hypokalaemia (<3.0 mmol/L)
occurred in 25 of the 184 prophylactic episodes (13.5%);
however, hypokalaemia grade IV (<2.5 mmol/L) was seen in
three cases only. Potassium was substituted in 21 and seven
cases, orally and intravenously, respectively; one patient was
hospitalized because of severe hypokalaemia.
TABLE 1. Patient characteristics
Patients with LAMB prophylaxis Historical controls
Number of patients (sex) 44 (24 male, 20 female) 39 (22 male, 17 female)
Number of casesa 46 45
Age (median (range)) 7.7 years (6 months to 21 years) 10 years (3 months to 16 years)
Underlying diagnosisa HR-ALL 13* HR-ALL 8**
ALL relapse 14 ALL relapse 8
AML 10 AML 18****
AML relapse 2 AML relapse 4
NHL 5* NHL 6
NHL relapse 1 SAA 1
SAA 1
Number of analysed episodesb 184 201
Duration of analysed episode (days) (median (range)) 24 (5–104) 28 (4–105)
Duration of ANC <500/lL (days) (median (range)) 10 (0–52) 12 (0–63)
Duration of ANC <1000/lL (days) (median (range)) 15 (3–121) 16 (1–75)
Number of episodes (%) with prolonged neutropenia
(ANC <500/lL for >10 days)
126 (68) 113 (57)
AML, acute myeloid leukaemia; ANC, absolute neutrophil count; HR-ALL, high-risk acute lymphoblastic leukaemia; LAMB, liposomal amphotericin B; NHL, non-Hodgkin lym-
phoma; SAA, severe aplastic anaemia.
aTwo patients of the LAMB group and six patients of the historical control group were analysed for both primary and recurrent malignancy (indicated by *).
bOnly 184 episodes were included in the analysis, as allergic reactions occurred in three patients during the ﬁrst administration of LAMB.
**, *** Represents a patient who was analyzed during both primary disease and relapse (as indicated in a).
FIG. 1. Median plasma levels of aspartate transaminase (AST), ala-
nine transaminase (ALT) and creatinine at baseline (white columns),
maximum values during prophylaxis with liposomal amphotericin B
(LAMB; light grey columns), and at end of treatment with LAMB
(dark grey columns). The error bars represent the 25th and 75th
quartiles, respectively. The horizontal dashed lines represent the
upper range of normal values in healthy individuals. For all parame-
ters assessed, baseline values and end-of-treatment values did not
differ signiﬁcantly, whereas maximum levels were signiﬁcantly higher
than baseline and end-of-treatment values (p <0.001 each). *165 U/L.
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Maximum levels of the hepatic transaminases aspartate
transaminase (AST) and alanine transaminase (ALT) during
LAMB prophylaxis (median (range), 59 U/L (19–1819 U/L)
and 83 U/L (17–2892 U/L), respectively) were signiﬁcantly
higher than baseline levels (median (range), 38 U/L (13–
229 U/L) and 38 U/L (5–456 U/L), respectively; p <0.001
each) and than levels at end of treatment (median (range),
37 U/L (5–185 U/L) and 37 U/L (8–375 U/L), respectively;
p <0.001 each) (Fig. 1). Levels of AST and ALT assessed at
end of treatment did not signiﬁcantly differ from baseline lev-
els (p 0.48 and p 0.14, respectively).
Efﬁcacy
After a median follow-up of 29 months after diagnosis
(range, 6–119 months), 36 patients of the LAMB group were
alive (81.8%). Eight patients died because of relapse or pro-
gression of the malignancy. Breakthrough IFD, deﬁned as
probable or proven IFD, did not occur in any patient while
on prophylaxis (Table 2). In one patient suffering from AML,
possible IFD was diagnosed. Febrile neutropenia occurred in
28 patients (68%) and in 57 of 184 antifungal prophylaxis epi-
sodes (31%) (Table 2). In 13 patients (32%) and 19 of the
184 prophylactic episodes (10%), empirical antifungal therapy
was instituted (Table 2).
Assessment of LAMB levels
In a randomly selected subset of the patients (n = 5), LAMB
trough and peak levels were determined after a median of
35 dosages of LAMB (range, 15–66). The median trough and
maximum levels were 0.64 lg/mL (range, 0.22–6.19 lg/mL)
and 27.5 lg/mL (range, 24.4–56.2 lg/mL), respectively.
Comparison with the historical control group
A total of 39 patients (22 boys; 201 analysed episodes) were
included in the historical control group. Six patients were
included twice in the analysis for primary disease and relapse
(Table 1). Twenty-four months after diagnosis, 26 patients of
the historical control group (66.6%) were alive, and 13
patients (33.3%) had died because of their underlying disease.
The median age of the patients was 10 years, and the median
duration of neutropenia per analysed episode was 12 days,
and thus comparable to the patients of the LAMB cohort. In
100 of the 201 analyzsed episodes (50.7%), no systemic anti-
fungal prophylaxis was given, whereas ﬂuconazole or itraco-
nazole was administered in 19 (9.5%) and 80 (39.8%) of the
episodes, respectively. Serum levels of itraconazole were not
routinely assessed at that time.
Five proven and two probable IFDs were observed in the
historical control group (Table 2). Speciﬁcally, proven/proba-
ble IFDs consisted of invasive aspergillosis (AML (n = 3), ALL
and non-Hodgkin lymphoma (n = 1 each)), cryptococcosis
(AML (n = 1)), and infection caused by Absidia corymbifera
(severe/very severe aplastic anaemia (n = 1)). Proven/proba-
ble IFDs occurred in six patients not receiving antifungal pro-
phylaxis and in one patient receiving itraconazole
prophylaxis. Possible IFDs were seen in ﬁve historical con-
trols. Importantly, the incidence of proven/probable IFD was
signiﬁcantly higher in historical controls than in the study
population with LAMB prophylaxis (0 vs. 7; p 0.01) (Table 2).
In contrast, the institution of empirical antifungal therapy was
comparable in both cohorts.
Calculation of the total acquisition cost of antifungal com-
pounds for both prophylaxis and therapy demonstrated that
the average costs per kilogram body weight or per paediatric
patient weighing 25 kg were €205 (±€129) and €5125
(±€3225) in the LAMB prophylaxis group, and €170 (±€380)
and €4250 (±€9500) for control patients (p 0.08).
Discussion
The results of this prospective cohort analysis suggest that
administration of LAMB twice weekly at a dosage of 2.5 mg/
kg is feasible and well tolerated, and is an effective preven-
tive antifungal approach for paediatric cancer patients at high
TABLE 2. Infectious complications in patients receiving pro-
phylaxis with liposomal amphotericin B (LAMB) and in his-
torical controls
Patients with
LAMB
prophylaxis,
no. (%)
Historical
controls,
no. (%)
p
Total
Patientsa 41 39
Casesa 43 45
Episodes 184 201
Proven IFD
Patients 0 5 (13) NS
Cases 0 5 (11) NS
Probable IFD 0.01
Patients 0 2 (5) NS
Cases 0 2 (4) NS
Possible IFD
Patients 1 (2) 5 (13) NS
Cases 1 (2) 5 (11) NS
Febrile neutropenic episode
Patients 28 (68) 33 (84) NS
Cases 28 (65) 38 (76) 0.05
Episodes 57 (31) 80 (40) NS
Empirical antifungal therapy
Patients 13 (32) 15 (38) NS
Cases 13 (30) 18 (40) NS
Episodes 19 (10) 25 (12) NS
IFD, invasive fungal disease; NS, not signiﬁcant.
aSeveral patients were included twice in the analysis, as they presented with
de novo malignancy and with relapse; note that only 41 patients (43 cases) of the
LAMB group were included in the analysis of infectious complications, as three
patients were excluded because of allergic reactions during the ﬁrst administra-
tion of LAMB.
)
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risk for IFD. In our study population, LAMB was prematurely
discontinued in four patients (9%), because of infusion-
related reactions Whereas the discontinuation rate in a ran-
domized study in adults who received 50 mg of LAMB every
other day as a 1-h infusion was 2.8% [14], similar or higher
rates of premature discontinuation were reported in children
receiving prophylactic LAMB at a dosage of 1 mg/kg as a
30-min infusion (19%), as well as in children receiving oral
itraconazole (11%) or voriconazole (18%) as antifungal pro-
phylaxis [15–17]. Notably, the use of mould-active antifungal
triazoles such as itraconazole or voriconazole for prophylaxis
in children is limited by the interaction with vinca alkaloids,
which constitute a cornerstone in the treatment of paediat-
ric leukaemia [5,6]. In addition, a recent survey reported on
low compliance of children on itraconazole prophylaxis [18].
Echinocandins are associated with fewer side effects [19–21]
than LAMB. However, because of the short half-life, echino-
candins have to be given intravenously on a daily basis, which
is not feasible in children suffering from acute leukaemia,
who, to a large extent, receive chemotherapy in an outpa-
tient setting.
The high frequency of abnormalities in laboratory values
in our group of high-risk patients while on LAMB prophy-
laxis was expected, given the serious nature of their under-
lying disorders and the multitude of concomitant
medications. However, median end-of-treatment values of
AST and ALT did not signiﬁcantly differ from their respec-
tive baseline values, and only a minority of patients had
mildly elevated creatinine values at end of treatment. Simi-
larly, hypokalaemia was usually mild, requiring hospitalization
of one patient only. These observations are in line with pre-
vious reports on LAMB prophylaxis in paediatric and adult
patients [14,15].
In our high-risk population, characterized by a median
duration of neutropenia of 10 days per episode, no proven
or probable IFD occurred, and pulmonary inﬁltrates compati-
ble with invasive mould infection were seen in only one
patient. This is in line with the ﬁndings in 16 children receiv-
ing LAMB (1 mg/kg) and in 74 adult transplant recipients
receiving LAMB (2 mg/kg) three times weekly [15,22]. Our
observation is also supported by a prospective, randomized,
open-label trial in adults with haematological malignancies
and prolonged neutropenia, in which patients receiving
50 mg LAMB every other day experienced signiﬁcantly less
proven/probable IFD than patients without systemic antifun-
gal prophylaxis [14]. Although the regimens of LAMB differed
between these studies, the assessment of trough samples in
our patient population demonstrated that LAMB plasma con-
centrations 4 days after the last infusion were close to the
MIC90s for susceptible strains (Candida, 0.25–1 mg/L; Aspergillus,
0.5–2 mg/L), indicating that twice-weekly dosing as described
in our study may provide useful protection against fungal
infections [9,23]. However, it is important to note that MICs
for amphotericin B have not correlated well with clinical out-
come when studied.
Unfortunately, a comparison of our results with reports
on other antifungal strategies in children is hampered by dif-
ferent inclusion criteria and different study endpoints. For
example, one prospective observational study analysing 44
episodes of prophylactic itraconazole in 39 paediatric cancer
patients did not report on breakthrough infection, but this
study included low-risk patients such as children with brain
tumours or Langerhans cell histiocytosis, who are consider-
ably less immunocompromised than our study population
[16]. It is important to note that most of the few reports on
antifungal prophylaxis in children are observational studies
without a comparison with a control group [15–17,24].
Therefore, because of the difﬁculties in performing well -
designed and sufﬁciently powered randomized studies on
antifungal prophylaxis, particularly in children, a comparison
with a historical control group might be a reasonable
approach [25]. Although we recognize the limitation of this
approach, we has to emphasize that our historical control
group was comparable to the study population with regard
to patient characteristics, chemotherapeutic regimens, diag-
nostic procedures, and supportive care measures, except for
the systemic antifungal prophylaxis analysed. In addition,
other parameters, such as the extent of construction work,
which is known to increase the risk for invasive aspergillosis,
did not differ between the two time periods analysed [26].
Whereas the incidence of proven/probable IFD in the histor-
ical controls is in line with the reported risk of IFD in this
patient population [1], it is signiﬁcantly higher than the inci-
dence of IFD in our study population, indicating that LAMB
prophylaxis is effective, and the calculation of the number
needed to treat results between nine and 11, depending on
the inclusion of possible IFD. Importantly, as the individual
genetic proﬁle was demonstrated to inﬂuence the risk and
severity of infectious complications [27,28], we performed
the analysis with the number of patients as denominator.
Whereas prophylactic LAMB twice weekly seems to
decrease the incidence of proven/probable IFD in paediatric
high-risk patients, the incidence of empirical antifungal ther-
apy was unaffected.
In contrast to adults, where signiﬁcant cost savings were
obtained by the institution of LAMB prophylaxis [29], our data
demonstrate that the costs of antifungal compounds were
comparable in the study population and historical controls.
However, it is important to note that we included in our anal-
ysis only acquisition costs of antifungal medication. As LAMB
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prophylaxis was usually administered in an outpatient setting
(except for the time when the patient was admitted to the
hospital for chemotherapy or for complications such as febrile
neutropenia), intermittent LAMB prophylaxis might improve
quality of life and ultimately reduce cost.
In conclusion, LAMB prophylaxis at a dosage of 2.5 mg/kg
twice weekly is feasible and safe, and appears to be effective
in preventing IFD in paediatric cancer patients at high risk.
On the basis of the data generated in this cohort study, this
approach is a reasonable alternative for antifungal prophylaxis
in patients in whom other agents are not appropriate.
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